Hofseth BioCare ASA
Hofseth BioCare ASA
07/03/2022 | Press release | Distributed by Public on 07/03/2022 12:42
Hofseth Biocare ASA: PRIVATE PLACEMENT SUCCESSFULLY PLACED
Tid03.07.2022, 18:32:32
MeldingsID566341
UtstederIDHBC
MarkedOslo Børs
Andre språk
Korrigerte versjoner
KategoriENDRINGER I RETTIGHETENE TIL AKSJER / VERDIPAPIRER
-
Informasjonspliktige opplysningerInformasjonspliktige opplysninger i henhold til lov, forskrift eller børsens egne regler for markedet verdipapiret er notert på.
-
Lagringspliktig meldingMed lagringspliktige meldinger menes meldinger som skal oppbevares i offisiell lagringsmekanisme (OAM) etter verdipapirhandelloven § 5-12 og/eller børsens egne regler.
Vedlegg
Del melding
Hofseth Biocare ASA: PRIVATE PLACEMENT SUCCESSFULLY PLACED
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER
JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE
SECURITIES DESCRIBED HEREIN.
(Ålesund, 3 July 2022) Reference is made to the stock exchange release from
Hofseth Biocare ASA ("HBC" or the "Company") published on 1 July 2022 regarding
a contemplated private placement.
The Company hereby announces that it has allocated 35,490,000 new shares in the
Company (the "Offer Shares") in a private placement (the "Private Placement") at
a subscription price of NOK 4.00 per Offer Share (the "Offer Price"), thereby
raising gross proceeds of approximately NOK 141 million. The Private Placement
was oversubscribed on the time of completion.
The net proceeds of the Private Placement will be used for general corporate
purposes. The Company is also in the process of securing more fresh salmon raw
material off-cuts from nearby external sources to enable the factory at Midsund
to operate above 80% capacity utilization at all times. The increase in demand
for HBC's human grade ingredients made from salmon by-products over the past 12
months has increased meaningfully from both the Petcare and nutraceutical
channels. There is now a strong pipeline building for which more consistent raw
materials input is required.
Notification of allotment of the Offer Shares including settlement instructions
will be sent to the applicants through a notification from the Company on or
about 4 July 2022. The Offer Shares will be settled towards the investors in the
Private Placement as soon as practicable after full payment has been received
and the share capital increase pertaining to the Private Placement has been
registered in the Norwegian Register of Business Enterprises. The Offer Shares
allocated in the Private Placement will be settled partially through cash
payment and partially through conversion of debt and outstanding trade credits
(a total of NOK 71,200,760).
In order to increase the share capital pertaining to the Private Placement, the
Company's board of directors has resolved to issue 35,490,000 new shares in the
Company pursuant to the authorization granted by the Company's annual general
meeting on 29 April 2022. As disclosed in the stock exchange notice from 1 July
2022, the share capital increase pertaining to the Private Placement has been
divided into two separate resolutions, pursuant to which Aqua-Spark will pay for
shares allocated to it within 24 July 2022. Consequently, the share capital of
the Company will be increased with NOK 354,900. Following registration of the
two resolutions to increase the share capital, the Company will have
393,321,030 shares outstanding, each with a par value of NOK 0.01.
Completion of the Private Placement remains subject to payment of all share
deposits and registration with the Norwegian Register of Business Enterprises of
the share capital increase in the Company pertaining to the Private Placement.
When resolving the issuance of the Offer Shares in the Private Placement, the
Company's board of directors considered the structure of the Private Placement
in light of the equal treatment obligations under the Norwegian Securities
Trading Act and Oslo Børs' Circular no. 2/2014 and is of the opinion that it was
in the common interest of the Company and its shareholders to raise equity
through the Private Placement. By structuring the equity raise as a private
placement, the Company was able to raise equity efficiently, with no discount to
the current trading price, at a lower cost and with a significantly lower risk
compared to a rights issue. Further, the Offer Price was fixed to a premium
towards the prevailing market price of the Company's shares. Based on the
foregoing, it is not planned to conduct a subsequent repair issue directed
towards shareholders not participating in the Private Placement. As a
consequence of the Private Placement structure, the shareholders' preferential
rights were deviated from.
Advokatfirmaet CLP DA acts as Norwegian legal counsel in connection with the
Private Placement.
For further information, please contact:
Jon Olav Ødegård, CFO at HBC
Phone: +47 936 32 966
E-mail: [email protected]
James Berger, CCO at HBC
Phone: +41 79 950 1034
E-mail: [email protected]
About HBC:
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung") as
well as in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as 'ProGo') as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.
The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. HBC's headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto.
HBC is listed on Oslo Børs with ticker "HBC". More information about HBC at
hofsethbiocare.com and facebook.com/hofsethbiocare.
This information was considered to be inside information pursuant to the EU
Market Abuse Regulation. This stock exchange announcement was published by Jon
Olav Ødegård, Chief Financial Officer, on the time and date provided.
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER
JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE
SECURITIES DESCRIBED HEREIN.
(Ålesund, 3 July 2022) Reference is made to the stock exchange release from
Hofseth Biocare ASA ("HBC" or the "Company") published on 1 July 2022 regarding
a contemplated private placement.
The Company hereby announces that it has allocated 35,490,000 new shares in the
Company (the "Offer Shares") in a private placement (the "Private Placement") at
a subscription price of NOK 4.00 per Offer Share (the "Offer Price"), thereby
raising gross proceeds of approximately NOK 141 million. The Private Placement
was oversubscribed on the time of completion.
The net proceeds of the Private Placement will be used for general corporate
purposes. The Company is also in the process of securing more fresh salmon raw
material off-cuts from nearby external sources to enable the factory at Midsund
to operate above 80% capacity utilization at all times. The increase in demand
for HBC's human grade ingredients made from salmon by-products over the past 12
months has increased meaningfully from both the Petcare and nutraceutical
channels. There is now a strong pipeline building for which more consistent raw
materials input is required.
Notification of allotment of the Offer Shares including settlement instructions
will be sent to the applicants through a notification from the Company on or
about 4 July 2022. The Offer Shares will be settled towards the investors in the
Private Placement as soon as practicable after full payment has been received
and the share capital increase pertaining to the Private Placement has been
registered in the Norwegian Register of Business Enterprises. The Offer Shares
allocated in the Private Placement will be settled partially through cash
payment and partially through conversion of debt and outstanding trade credits
(a total of NOK 71,200,760).
In order to increase the share capital pertaining to the Private Placement, the
Company's board of directors has resolved to issue 35,490,000 new shares in the
Company pursuant to the authorization granted by the Company's annual general
meeting on 29 April 2022. As disclosed in the stock exchange notice from 1 July
2022, the share capital increase pertaining to the Private Placement has been
divided into two separate resolutions, pursuant to which Aqua-Spark will pay for
shares allocated to it within 24 July 2022. Consequently, the share capital of
the Company will be increased with NOK 354,900. Following registration of the
two resolutions to increase the share capital, the Company will have
393,321,030 shares outstanding, each with a par value of NOK 0.01.
Completion of the Private Placement remains subject to payment of all share
deposits and registration with the Norwegian Register of Business Enterprises of
the share capital increase in the Company pertaining to the Private Placement.
When resolving the issuance of the Offer Shares in the Private Placement, the
Company's board of directors considered the structure of the Private Placement
in light of the equal treatment obligations under the Norwegian Securities
Trading Act and Oslo Børs' Circular no. 2/2014 and is of the opinion that it was
in the common interest of the Company and its shareholders to raise equity
through the Private Placement. By structuring the equity raise as a private
placement, the Company was able to raise equity efficiently, with no discount to
the current trading price, at a lower cost and with a significantly lower risk
compared to a rights issue. Further, the Offer Price was fixed to a premium
towards the prevailing market price of the Company's shares. Based on the
foregoing, it is not planned to conduct a subsequent repair issue directed
towards shareholders not participating in the Private Placement. As a
consequence of the Private Placement structure, the shareholders' preferential
rights were deviated from.
Advokatfirmaet CLP DA acts as Norwegian legal counsel in connection with the
Private Placement.
For further information, please contact:
Jon Olav Ødegård, CFO at HBC
Phone: +47 936 32 966
E-mail: [email protected]
James Berger, CCO at HBC
Phone: +41 79 950 1034
E-mail: [email protected]
About HBC:
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung") as
well as in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as 'ProGo') as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.
The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. HBC's headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto.
HBC is listed on Oslo Børs with ticker "HBC". More information about HBC at
hofsethbiocare.com and facebook.com/hofsethbiocare.
This information was considered to be inside information pursuant to the EU
Market Abuse Regulation. This stock exchange announcement was published by Jon
Olav Ødegård, Chief Financial Officer, on the time and date provided.